ArticlePediatric nephrology (Berlin, Germany)2008
Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years.
Article in Pediatric nephrology (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Immunosuppressive agents for frequently relapsing/steroid-dependent nephrotic syndrome in children: a systematic review and network meta-analysis.Frontiers in immunology · 2024Pooled it
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2009Trial
- Corticosteroids augment cyclosporine nephrotoxicity in pediatric nephrotic syndrome: potential role of alternatively activated macrophages.Pediatric nephrology (Berlin, Germany) · 2026Article
- Factors associated with chronic calcineurin inhibitor nephrotoxicity in children with minimal-change disease.Renal failure · 2025Article
- Pathogenesis and Management of Acute Kidney Injury in Patients with Nephrotic Syndrome Due to Primary Glomerulopathies.Medicina (Kaunas, Lithuania) · 2019Review
- Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.Medicine · 2014Article
- Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction.Experimental and therapeutic medicine · 2014Article
- Calcineurin inhibitor induced nephrotoxicity in steroid resistant nephrotic syndrome.Indian journal of nephrology · 2013Article
- Chapter 3: Steroid-sensitive nephrotic syndrome in children.Kidney international supplements · 2012Article
- Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome.Clinical journal of the American Society of Nephrology : CJASN · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of cyclosporine A (CsA) therapy in patients with steroid-dependent nephrotic-syndrome (SDNS) on long-term renal function is controversial. Data beyond 5 years are rare. Long-term renal function was evaluated in children with SDNS with and without CsA therapy, especially beyond 5 years. Twenty children were treated with CsA (study group) for a mean of 5.4 +/- 2.2 years (ten patients for 5-11 years). Glomerular filtration rate (GFR) was calculated before and after 3 and 12 months and at latest follow-up of therapy. Fifteen children with cyclophosphamide-treated SDNS without CsA served as controls. In the study group, GFR decreased within 12 months from 136 +/- 19 to 120 +/- 31, to 114 +/- 14 ml/min per 1.73 m(2) at latest follow-up (p < 0.0001). Patients with CsA > 5 years had a GFR of 111 +/- 14 ml/min per 1.73 m(2) at latest follow-up without a GFR below 90 ml/min per 1.73 m(2). No CsA toxicity was found in biopsies. In the control group, GFR dropped within 3 months, from 137 +/- 27 to 130 +/- 24, to 126 +/- 19 ml/min per 1.73 m(2) at latest follow-up (p = 0.1). Patients with and without nephrotoxic CsA therapy showed a drop in GFR. In CsA-treated patients, GFR was about 12% lower at latest follow-up compared with patients without nephrotoxic therapy but always remained within normal range. CsA seems to be safe, even in long-term treatment for more than 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.